Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis
Public ClinicalTrials.gov record NCT03350815. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Parallel-group, Multicenter Study of Secukinumab to Compare 300 mg and 150 mg at Week 52 in Patients With Ankylosing Spondylitis Who Are Randomized to Dose Escalation After Not Achieving Inactive Disease During an Initial 16 Weeks of Open-label Treatment With Secukinumab 150 mg (ASLeap)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This was a study estimating the clinical difference between 300 mg and 150 mg of secukinumab following dose escalation to 300 mg in patients with ankylosing spondylitis
Study identification
- NCT ID
- NCT03350815
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 322 participants
Conditions and interventions
Conditions
Interventions
- 150 mg open-label secukinumab Drug
- 150 mg double-blinded secukinumab Drug
- 300 mg double-blinded secukinumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 13, 2018 (Actual)
- Primary completion
- Mar 11, 2021 (Actual)
- Completion
- May 29, 2021 (Actual)
- Last update posted
- Apr 29, 2022
2018 – 2021
United States locations
- U.S. sites
- 65
- U.S. states
- 27
- U.S. cities
- 63
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Jonesboro | Arkansas | 72401 | — |
| Novartis Investigative Site | Fullerton | California | 92835 | — |
| Novartis Investigative Site | Loma Linda | California | 92354 | — |
| Novartis Investigative Site | Palm Desert | California | 92260 | — |
| Novartis Investigative Site | Tustin | California | 92780 | — |
| Novartis Investigative Site | Upland | California | 91786 | — |
| Novartis Investigative Site | Aventura | Florida | 33180 | — |
| Novartis Investigative Site | Boca Raton | Florida | 33486 | — |
| Novartis Investigative Site | Brandon | Florida | 33511 | — |
| Novartis Investigative Site | DeLand | Florida | 32720 | — |
| Novartis Investigative Site | Gainesville | Florida | 32608 | — |
| Novartis Investigative Site | Orlando | Florida | 32810 | — |
| Novartis Investigative Site | Plantation | Florida | 33324 | — |
| Novartis Investigative Site | St. Petersburg | Florida | 33705 | — |
| Novartis Investigative Site | Tamarac | Florida | 33321 | — |
| Novartis Investigative Site | Tampa | Florida | 33609 | — |
| Novartis Investigative Site | Zephyrhills | Florida | 33542 | — |
| Novartis Investigative Site | Duluth | Georgia | 30096 | — |
| Novartis Investigative Site | Springfield | Illinois | 62703 | — |
| Novartis Investigative Site | Vernon Hills | Illinois | 60061 | — |
| Novartis Investigative Site | Evansville | Indiana | 47715 | — |
| Novartis Investigative Site | Monroe | Louisiana | 71203 | — |
| Novartis Investigative Site | Cumberland | Maryland | 21740 | — |
| Novartis Investigative Site | Hagerstown | Maryland | 21740 | — |
| Novartis Investigative Site | Wheaton | Maryland | 20902 | — |
| Novartis Investigative Site | Boston | Massachusetts | 02111 | — |
| Novartis Investigative Site | Worcester | Massachusetts | 01655 | — |
| Novartis Investigative Site | Ann Arbor | Michigan | 48109 5271 | — |
| Novartis Investigative Site | Saint Clair Shores | Michigan | 48081 | — |
| Novartis Investigative Site | Edina | Minnesota | 55435 | — |
| Novartis Investigative Site | Springfield | Missouri | 65810 | — |
| Novartis Investigative Site | Midland Park | New Jersey | 07432 | — |
| Novartis Investigative Site | Voorhees Township | New Jersey | 08043 | — |
| Novartis Investigative Site | Albuquerque | New Mexico | 87102 | — |
| Novartis Investigative Site | Santa Fe | New Mexico | 87505 | — |
| Novartis Investigative Site | Brooklyn | New York | 11201 | — |
| Novartis Investigative Site | New York | New York | 10016 | — |
| Novartis Investigative Site | Orchard Park | New York | 14127 | — |
| Novartis Investigative Site | Potsdam | New York | 13676 | — |
| Novartis Investigative Site | Minot | North Dakota | 58701 | — |
| Novartis Investigative Site | Cincinnati | Ohio | 45219 | — |
| Novartis Investigative Site | Dayton | Ohio | 45402 | — |
| Novartis Investigative Site | Middleburg Heights | Ohio | 44130 | — |
| Novartis Investigative Site | Oklahoma City | Oklahoma | 73103 | — |
| Novartis Investigative Site | Corvallis | Oregon | 97330 | — |
| Novartis Investigative Site | Portland | Oregon | 97239 | — |
| Novartis Investigative Site | Duncansville | Pennsylvania | 16635 | — |
| Novartis Investigative Site | Wexford | Pennsylvania | 15090 | — |
| Novartis Investigative Site | Charleston | South Carolina | 29460 | — |
| Novartis Investigative Site | Columbia | South Carolina | 29204 | — |
| Novartis Investigative Site | Jackson | Tennessee | 38305 | — |
| Novartis Investigative Site | Memphis | Tennessee | 38119 | — |
| Novartis Investigative Site | Beaumont | Texas | 77701 | — |
| Novartis Investigative Site | Colleyville | Texas | 76034 | — |
| Novartis Investigative Site | Dallas | Texas | 75231 | — |
| Novartis Investigative Site | Houston | Texas | 77025 | — |
| Novartis Investigative Site | Houston | Texas | 77089 | — |
| Novartis Investigative Site | Mesquite | Texas | 75150 | — |
| Novartis Investigative Site | Salt Lake City | Utah | 84132 | — |
| Novartis Investigative Site | Seattle | Washington | 98104 | — |
| Novartis Investigative Site | Seattle | Washington | 98195 | — |
| Novartis Investigative Site | Spokane | Washington | 99204 | — |
| Novartis Investigative Site | Charleston | West Virginia | 25304 | — |
| Novartis Investigative Site | Manitowoc | Wisconsin | 54220 | — |
| Novartis Investigative Site | Onalaska | Wisconsin | 54650 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03350815, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 29, 2022 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03350815 live on ClinicalTrials.gov.